A Phase 2 Study of Belzutifan (PT2977, MK-6482) for the Treatment of Von Hippel Lindau (VHL) Disease-Associated Renal Cell Carcinoma (RCC) (MK-6482-004)

Inclusion Criteria:

Has a diagnosis of von Hippel Lindau disease, based on a germline VHL alteration
Has at least 1 measurable solid RCC tumor and no RCC tumor that requires immediate surgical intervention. The diagnosis of RCC can be radiologic (histologic diagnosis not required). Participants may have VHL disease-associated tumors in other organ systems

Exclusion Criteria:

Has received prior treatment with belzutifan or another HIF-2α inhibitor
Has had any systemic anti-cancer therapy (includes anti-vascular endothelial growth factor [VEGF] therapy or any systemic investigational anti-cancer agent)
Has an immediate need for surgical intervention for tumor treatment
Has evidence of metastatic disease on screening imaging